Pharmaceuticals 2010, 3(4), 1084-1092; doi:10.3390/ph3041084
Review

Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease

Department of Gastroenterology, Rambam Health Care Campus, Haifa, P.O.B. 9602, Haifa, 31096, Israel
* Author to whom correspondence should be addressed.
Received: 13 January 2010; in revised form: 1 April 2010 / Accepted: 9 April 2010 / Published: 12 April 2010
(This article belongs to the Special Issue Non-Steroidal Anti-Inflammatory Drugs)
PDF Full-text Download PDF Full-Text [155 KB, uploaded 12 April 2010 09:57 CEST]
Abstract: Inflammatory Bowel Diseases (IBD) are an immune mediated chronic or relapsing disorders of the gastrointestinal (GI) tract. IBD is characterized by a chronic intestinal inflammatory process with various components contributing to the pathogenesis of the disease including environmental factors such as smoking or use of Non Steroidal Anti-Inflammatory Drugs (NSAIDS). NSAIDS are among the most commonly used medications for the treatment of various inflammatory conditions. The main factor limiting NSAIDS use is the concern for the development of gastrointestinal toxicity including mucosal injury. A possible association between the use of NSAIDS and the onset or relapse of IBD has been repeatedly suggested. This article will review the current concepts and evidence of the relationship between IBD and NSAIDS.
Keywords: NSAIDs; IBD; Crohn's; Ulcerative Colitis

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Klein, A.; Eliakim, R. Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease. Pharmaceuticals 2010, 3, 1084-1092.

AMA Style

Klein A, Eliakim R. Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease. Pharmaceuticals. 2010; 3(4):1084-1092.

Chicago/Turabian Style

Klein, Amir; Eliakim, Rami. 2010. "Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease." Pharmaceuticals 3, no. 4: 1084-1092.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert